PEPCID PRESERVATIVE FREE (famotidine) by Merck & Co. is histamine h2 receptor antagonists [moa]. First approved in 1986.
Drug data last refreshed Yesterday
PEPCID PRESERVATIVE FREE is an injectable formulation of famotidine, a histamine H2 receptor antagonist that reduces gastric acid secretion. It is indicated for gastroesophageal reflux disease, heartburn, and peptic ulcer disease. The preservative-free formulation targets institutional and high-acuity settings where patients require parenteral acid suppression.
Approaching loss of exclusivity with moderate competitive pressure (30%) signals shrinking team and defensive market positioning strategies.
Histamine H2 Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
Worked on PEPCID PRESERVATIVE FREE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PEPCID PRESERVATIVE FREE offers limited career growth due to LOE-approaching status, zero linked jobs, and a shrinking institutional market dominated by superior PPI competitors. Career trajectory would focus on defensive strategy, stakeholder management, and potential product transition or discontinuation planning.